# Pre-Approval Access to JNJ-53718678 for the Treatment of Respiratory Syncytial Virus (RSV) Infection in (a) Immunocompromised Adult and Pediatric Participants

> **NCT04221412** · — · NO_LONGER_AVAILABLE · sponsor: **Janssen Sciences Ireland UC**

## Conditions studied

- Respiratory Syncytial Virus

## Interventions

- **DRUG:** JNJ-53718678

## Key facts

- **NCT ID:** NCT04221412
- **Lead sponsor:** Janssen Sciences Ireland UC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2022-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04221412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04221412, "Pre-Approval Access to JNJ-53718678 for the Treatment of Respiratory Syncytial Virus (RSV) Infection in (a) Immunocompromised Adult and Pediatric Participants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04221412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*